The Patent Finder

Kangstem Biotech Co., Ltd.

10 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 22, 2027
    The maintenance fee for Composition for Preventing or Treating Inflammatory Diseases, Containing, as Active Ingredient, Stem Cells Overexpressing SOD3 (US 11,730,766) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
  • 1 fee due Mar 22, 2027
    The maintenance fee for CD49F promoting proliferation, multipotency and reprogramming of adult stem cells through PI3K/AKT/GSK3 pathway (US 9,139,812) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
  • 1 fee due Sep 22, 2027
    The maintenance fee for Equine amniotic fluid-derived multipotent stem cells and a method for producing the same (US 9,290,739) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

PatentTitleStatus Expires Confidence
US 9,139,812CD49F promoting proliferation, multipotency and reprogramming of adult stem cells through PI3K/AKT/GSK3 pathway
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,408,873Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,290,739Equine amniotic fluid-derived multipotent stem cells and a method for producing the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,650,604Equine amniotic membrane-derived mesenchymal stem cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,771,555Canine amniotic membrane-derived multipotent stem cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,512,285Method of Preparing Induced Neural Stem Cells Reprogrammed from Non-Neuronal Cells Using HMGA2
In force
 · High confidence
In forceHigh confidence
US 11,730,766Composition for Preventing or Treating Inflammatory Diseases, Containing, as Active Ingredient, Stem Cells Overexpressing SOD3
In force
 · High confidence
In forceHigh confidence
US 12,350,295Complex for promoting cartilage differentiation comprising cartilage cell-free crush and stem cell and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US D1,054,587Storage box for vial bottles
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,589,116Method for Producing Umbilcal Cord Blood-Derived Stem Cell with Enhanced Efficacy
In force
 · High confidence
In forceHigh confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

13 pending · 2 abandoned · 3 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited